Journal Title：Patient-patient Centered Outcomes Research

The Patient provides a venue for scientifically rigorous, timely, and relevant research to promote the development, evaluation and implementation of therapies, technologies, and innovations that will enhance the patient experience. It is an international forum for research that advances and/or applies qualitative or quantitative methods to promote the generation, synthesis, or interpretation of evidence.

The journal has specific interest in receiving original research, reviews and commentaries related to qualitative and mixed methods research, stated-preference methods, patient reported outcomes, and shared decision making.

Advances in regulatory science, patient-focused drug development, patient-centered benefit-risk and health technology assessment will also be considered.

Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in The Patient may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.

All manuscripts are subject to peer review by international experts.

《患者》雜志為科學嚴謹、及時和相關的研究提供了一個平臺，以促進治療、技術和創(chuàng)新的開發(fā)、評估和實施，從而改善患者的體驗。這是一個國際研究論壇，旨在推進和/或應用定性或定量方法來促進證據(jù)的生成、綜合或解釋。

該雜志特別希望收到與定性和混合方法研究、陳述偏好方法、患者報告結果和共同決策相關的原創(chuàng)研究、評論和評論。

監(jiān)管科學、以患者為中心的藥物開發(fā)、以患者為中心的效益風險和健康技術評估方面的進展也將得到考慮。

其他數(shù)字功能（包括動畫摘要、視頻摘要、幻燈片、音頻幻燈片、教學視頻、信息圖表、播客和動畫）可以與文章一起發(fā)布；這些旨在提高期刊內(nèi)容的知名度、讀者群和教育價值。此外，《患者》雜志上發(fā)表的文章可能附有通俗易懂的語言摘要，以幫助對該領域有一定了解但不具備深入專業(yè)知識的讀者了解重要的醫(yī)學進展。

所有稿件均需經(jīng)過國際專家的同行評審。

Patient-patient Centered Outcomes Research創(chuàng)刊于2008年，由Springer International Publishing出版商出版，收稿方向涵蓋HEALTH CARE SCIENCES & SERVICES全領域，此刊是中等級別的SCI期刊，所以過審相對來講不是特別難，但是該刊專業(yè)認可度不錯，仍然是一本值得選擇的SCI期刊 。平均審稿速度 12周，或約稿 ，影響因子指數(shù)3.4，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。